New Market Research Report: Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review,
Global Markets Direct's, 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections. Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets ...http://www.sbwire.com/press-releases/new-market-research-report-vancomycin-resistant-enterococcus-faecium-infections-pipeline-review-h2-2013-302216.htm
Enterococcus Faecium Infections - Pipeline Review, H2 2012 New Report | Oct 2, 2012 - ReleaseWire
Press Release issued Oct 2, 2012: Enterococcus Faecium Infections - Pipeline Review, H2 2012, provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. 'Enterococcus Faecium Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.http://www.sbwire.com/press-releases/enterococcus-faecium-infections-pipeline-review-h2-2012-new-report-168803.htm
Increase in Bloodstream Infection Due to Vancomycin-Susceptible Enterococcus faecium in Cancer Patients: Risk Factors,...
We conducted a prospective study to assess the risk factors, molecular epidemiology and outcome of bloodstream infection (BSI) due to Enterococcus faecium in hospitalized cancer patients. Between 2006 and 2012, a significant increase in vancomycin-susceptible E. faecium BSI was observed among cancer patients. Comparison of 54 episodes of BSI due to E. faecium with 38 episodes of BSI due to E. faecalis showed that previous use of carbapenems was the only independent risk factor for E. faecium acquisition (OR 10.24; 95% CI, 1.35-77.66). All E. faecium isolates were susceptible to glycopeptides, whereas 97% showed high-level resistance to ampicillin and ciprofloxacin. All 30 isolates available for genotyping belonged to the hospital-associated E. faecium lineages 17, 18 and 78. After 2009, most of the isolates belonged to ST117 (lineage 78). Patients with E. ...http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0074734
AID 68576 - The compound was evaluated for minimum inhibitory concentration against vancomycin resistant Enterococcus faecium ...
BioAssay record AID 68576 submitted by ChEMBL: The compound was evaluated for minimum inhibitory concentration against vancomycin resistant Enterococcus faecium (VRE);Not determined.https://pubchem.ncbi.nlm.nih.gov/bioassay/68576
Risk Factors Associated with the Development of Infection with Linezolid- and Vancomycin-Resistant Enterococcus faecium :...
This retrospective cohort study revealed that linezolid resistance in vancomycin-resistant Enterococcus faecium was dependent on prior linezolid exposure and duration of linezolid therapy. These strains of E. faecium were resistant to the entire class of oxazolidinones.. ...http://oxfordindex.oup.com/view/10.1086/344177
AID 408744 - Antimicrobial activity against vancomycin-resistant Enterococcus faecium FN-1 by microdilution susceptibility test...
BioAssay record AID 408744 submitted by ChEMBL: Antimicrobial activity against vancomycin-resistant Enterococcus faecium FN-1 by microdilution susceptibility test.https://pubchem.ncbi.nlm.nih.gov/bioassay/408744
Abstract: Daptomycin Plus Ceftaroline Against Daptomycin-Resistant <i>Enterococcus faecium </i>in a Rat Model of Experimental...
Background: Vancomycin-resistant Enterococcus faecium are difficult nosocomial pathogens to treat. Daptomycin (DAP) is a key front-line bactericidal antibiotic against VRE. Development of DAP resistance during therapy raises concerns about the role of DAP monotherapy in severe enterococcal infections. Limited previous data suggest that ceftaroline (CPT) enhances the in vitro activity of DAP against enterococci. We sought to evaluate the in vivo activity of DAP plus CPT against a DAP-R strain of E. faecium using an experimental infective endocarditis (IE) rat model. Methods: MICs and time-kill assays were performed using standard methods. IE was produced in carotid artery and jugular vein catheterized rats by intracardiac inoculation of 10X the ID90 of E. faecium HOU497. Therapy (3 days, via infusion pump) was begun 24 h after inoculation. Some animals were sacrificed at the time of therapy ...https://idsa.confex.com/idsa/2016/webprogram/Paper56612.html
AID 519097 - Antimicrobial activity against Enterococcus faecium isolate 3 from abdominal wound of patient by Etest - PubChem
BioAssay record AID 519097 submitted by ChEMBL: Antimicrobial activity against Enterococcus faecium isolate 3 from abdominal wound of patient by Etest.https://pubchem.ncbi.nlm.nih.gov/bioassay/519097
Enterococcus faecium, coccus prokaryote, SEM - Stock Image C032/2584 - Science Photo Library
Coloured scanning electron micrograph (SEM) of Enterococcus faecium (also known as Streptococcus faecium), Gram-positive, vancomycin resistant (VRE), coccus prokaryote that grows in groups or chains. E. faecium is commonly found in the guts of humans and other animals. It does not normally cause disease, but can be an opportunistic pathogen when the immune system is impaired. It is an important nosocomial (hospital-acquired) pathogen. E. faecium is known to have a resistance to several types of antibiotics including gentamicin, tetracycline, erythromycin, teicoplanin and penicillin. Magnification: x3,405 when shortest axis printed at 25 millimetres. - Stock Image C032/2584http://www.sciencephoto.com/media/799403/view
Virulence determinants in vancomycin-resistant **Enterococcus faecium vanB**: clonal distribution, prevalence and significance...
Virulence determinants in vancomycin-resistant **Enterococcus faecium vanB**: clonal distribution, prevalence and significance of **esp** and **hyl** in Australian patients with haematological disorders ...https://repository.uantwerpen.be/link/irua/68233
Emergence of Vancomycin-Resistant Enterococci - Volume 7, Number 2-April 2001 - Emerging Infectious Disease journal - CDC
Vancomycin and ampicillin resistance in clinical Enterococcus faecium strains has developed in the past decade. Failure to adhere to strict infection control to prevent the spread of these pathogens has been well established. New data implicate the use of specific classes of antimicrobial agents in the spread of vancomycin-resistant enterococci (VRE). Extended-spectrum cephalosporins and drugs with potent activity against anaerobic bacteria may promote infection and colonization with VRE and may exert different effects on the initial establishment and persistence of high-density colonization. Control of VRE will require better understanding of the mechanisms by which different classes of drugs promote gastrointestinal colonization.https://wwwnc.cdc.gov/eid/article/7/2/70-0183_article
Validation of baking to control Salmonella serovars in hamburger bun manufacturing, and evaluation of Enterococcus faecium ATCC...
With the implementation of the Food and Drug Administration's Food Safety Modernization Act, the food industry must scientifically verify that current production processes provide sufficient protection against pathogens. This study was conducted to validate a simulated commercial baking process for hamburger buns to control Salmonella spp. contamination and to determine the appropriateness of using non-pathogenic surrogates (Enterococcus faecium ATCC 8459 or Saccharomyces cerevisiae) for in-plant process validation studies. Wheat flour was separately inoculated (~6 log CFU/g) with three Salmonella serovars (Typhimurium, Newport or Senftenberg) or E. faecium. Dough was formed, proofed, and baked to mimic commercial manufacturing conditions. Non-inoculated dough was used to evaluate S. cerevisiae (Baker's yeast) survival during baking. Buns were baked for 9, 11 and 13 min in a conventional oven set at 218°C, with internal bun temperature profiles recorded. ...http://krex.k-state.edu/dspace/handle/2097/20546
AID 68231 - Compound was tested for the inhibition of cell wall biosynthesis and growth against Enterococcus faecium (ATCC51559...
BioAssay record AID 68231 submitted by ChEMBL: Compound was tested for the inhibition of cell wall biosynthesis and growth against Enterococcus faecium (ATCC51559) (Vancomycin-resistant).https://pubchem.ncbi.nlm.nih.gov/bioassay/68231
Repositorio da Producao Cientifica e Intelectual da Unicamp: Clonal dissemination of VanA-type glycopeptide-resistant...
Nosocomial dissemination of glycopeptide-resistant enterococci represents a major problem in hospitals worldwide. In Brazil, the dissemination among hospitals in the city of São Paulo of polyclonal DNA profiles was previously described for vancomycin-resistant Enterococcus faecium. We describe here the dissemination of VanA phenotype E. faecalis between two hospitals located in different cities in the State of São Paulo. The index outbreak occurred in a tertiary care university hospital (HCUSP) in the city of São Paulo and three years later a cluster caused by the same strain was recognized in two patients hospitalized in a private tertiary care hospital (CMC) located 100 km away in the interior of the state. From May to July 1999, 10 strains of vancomycin-resistant E. faecalis were isolated from 10 patients hospitalized in the HCUSP. The DNA genotyping using pulsed-field gel electrophoresis (PFGE) showed that all isolates were originated from the same ...http://repositorio.unicamp.br/jspui/handle/REPOSIP/24231
Enterococcus faecium (Orla-Jensen) Schleifer and Kilpper-Balz ATCC &re
Enterococcus faecium ATCC ® 700221™ Designation: VRE TypeStrain=False Application: Quality control strain Quality control strain for IDEXX productshttps://www.atcc.org/en/Products/Cells_and_Microorganisms/Microbial_Panels/Vancomycin-Resistant_Enterococci_Panel/700221.aspx
Enterococcus faecium (Orla-Jensen) Schleifer and Kilpper-Balz ATCC &re
Enterococcus faecium ATCC ® 35667™ Designation: LRA 55 03 77 TypeStrain=False Application: Quality control strain Quality control strain for API products Water testinghttps://www.atcc.org/Products/Collections/Preceptrol_Cultures/35667.aspx?slp=1
Enterococcus faecium (Orla-Jensen) Schleifer and Kilpper-Balz ATCC &re
Enterococcus faecium ATCC ® 35667™ Designation: LRA 55 03 77 TypeStrain=False Application: Quality control strain Quality control strain for API products Water testinghttps://www.atcc.org/Products/Quality_Control_Strains/By_Organization__Company/35667.aspx
Effect of short-term probiotic Enterococcus faecium SF68 dietary supplementation in overweight and obese cats without...
The high incidence of obesity in pet cats is a growing concern, and this problem is associated with serious diseases. Studies in mice models and human beings have shown that probiotics can reduce food intake, promote weight loss and improve metabolic profile (Aronsson and others 2010, Andersson and others 2010a, b, Takemura and others 2010, Everard and others 2011, Neyrinck and others 2012, Sanchez and others 2014, Zarrati and others 2014); however, similar studies are absent in cats. The study reported here did not identify any significant change within or between the control and probiotic E faecium SF68 supplementation group with respect to bodyweight, body condition score, lean body mass, fat mass per cent, blood glucose, cholesterol, triglyceride, insulin, fructosamine, leptin and total adiponectin concentrations after eight weeks of intervention and six weeks after discontinuation. Although daily food intake was significantly decreased after eight weeks of intervention and six weeks ...http://vetrecordopen.bmj.com/content/3/1/e000164
Genetics of Aquatic Organisms
1 Central Fisheries Research Institute, Trabzon, Turkey DOI : 10.4194/2459-1831-v1_1_02 Viewed : 348 - Downloaded : 247 Antibiotic resistance and presence of the resistance genes were investigated in the Vancomycin Resistant Enterococci (VRE) isolated from sediment in cage areas. A total of 85 Enterococcus faecium strains were isolated from the sediment samples. The Minimum Inhibitory Concentration (MIC) tests were indicated that, 16.47% of the E. faecium strains resistant to vancomycin. Following the detection of antimicrobial susceptibilities of the isolates, occurrence of the vancomycin resistance genes (vanA, vanB, vanC1) were determined by PCR. At least one vancomycin resistance gene was found in 64.7% of the E. faecium strains. The vanA, vanB and vanC1 genes were determined in 29.41%, 31.76% and 25.88% of the bacteria ...http://genaqua.org/abstract.php?lang=en&id=4
Protective Effect of Probiotic Enterococcus faecium NCIM 5593 on Acrylamide Induced Neurotoxicity in Adult Mice | Open Access...
Exposure to chemicals that are commonly distributed in the environment and work-related surroundings may have deleterious effects to the nervous system. Acrylamide (ACR..https://www.omicsonline.org/open-access/protective-effect-of-probiotic-enterococcus-faecium-ncim-5593-onacrylamide-induced-neurotoxicity-in-adult-mice-2329-8901-1000165.php?aid=89037
Munin: Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide...
To estimate the relative fitness differences between glycopeptide-resistant Enterococcus faecium (GREF) and glycopeptide-susceptible E. faecium (GSEF) from yearly surveillance data on the occurrence of GREF in Danish poultry farm environments. A population genetic model was adapted to retrospectively estimate the biological fitness cost of acquired resistance. Maximization of a likelihood function was used to predict the longitudinal persistence of acquired resistance. Our analysis suggests strong selection against GREF following the 1995 ban on the glycopeptide growth promoter avoparcin. However, parameterizing the model with two selection coefficients suggesting a reduced negative effect of the acquired resistance on bacterial fitness over time significantly improved the fit of the model. Our analyses suggest that the acquired glycopeptide resistance will persist for >25 ...https://munin.uit.no/handle/10037/3847
Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy.
OBJECTIVE: To test the hypothesis that antibiotic therapy may promote recurrence of vancomycin-resistant Enterococcus (VRE) stool colonization in patients who have previously had three consecutive negative stool cultures obtained at least 1 week aparhttp://www.biomedsearch.com/nih/Recurrence-vancomycin-resistant-Enterococcus-stool/12186208.html
Vancomycin-Resistant Enterococcus, Molecular Detection, PCR - Hallmark Health
The high sensitivity of amplification by PCR requires the specimen to be processed in an environment in which contamination of the specimen by Vancomycin-Resistant Enterococcus DNA is unlikely.. Submit only 1 of the following specimens:. Supplies:. Culturette (BBL Culture Swab) (T092). C and S Vial (T058). Stool container, Small (Random), 4 oz Random (T288). Preferred:. Specimen Type: Perianal, perirectal, rectal. Container/Tube: Culture transport swab (Dacron or rayon swab with aluminum or plastic shaft with either Stuart or Amies liquid medium [T092]). Specimen Volume: Swab. Acceptable:. Specimen Type: Preserved Stool. Container/Tube: Commercially available transport system specific for recovery of enteric pathogens from fecal specimens (15 mL of non-nutritive transport medium containing phenol red as a pH indicator, either Cary-Blair, Para-Pak C and S [T058]). Specimen Volume: Representative portion of stool. Collection Instructions:. 1. Collect fresh stool and submit 1 gram or 5 mL in ...http://hallmarkhealthsystem.testcatalog.org/show/VRERP
Institute of Applied Science: MSc: Pritesh Prasad
My research project aims at finding bioactive compounds from a marine sponge, family Halichondriidae. This involves extraction/isolation, purification and structure elucidation of the bioactive compound(s).. The extraction procedure employs liquid-liquid partitioning of the crude extract in order to obtain Hexane, Dichloromethane, Butan-2-ol and Methanol fractions. Further fractionation carried out by flash column chromatography follows bioassay (bioassay guided fractionation). The bioassay involves tests against Vancomycin-resistant Enterococcus faecium (VREF), Methicillin-resistant Staphylococcus aureus (MRSA), wild type Staphylococcus aureus (WTSA), Wild-type Candida albicans (WTCA) and Amphotericin B- resistant Candida albicans (ARCA). Brine Shrimp assay (general cytotoxicity) is also carried out for the crude and fractions. The bioactive extracts are further subjected to semi-preparative High Performance Liquid Chromatography (HPLC) for purifications followed by ...https://www.usp.ac.fj/index.php?id=19242&type=98
Successful oral therapy switch to trimethoprim/sulfamethoxazole in the case of an Enterococcus faecium liver abscess
Autori: Popescu GA, Gavriliu L, Popescu C, Popoiu M, Popa G.. Editorial: The Journal of Antimicrobial Chemotherapy, 62, p.424-5, 2008.. Rezumat:. Cuvinte cheie: intravenous-to-oral switch therapy, intraabdominal abscess, enterococcal infection. URL: http://jac.oxfordjournals.org/content/62/2/424.long. ...http://ad-astra.ro/2012/09/02/successful-oral-therapy-switch-to-trimethoprim-sulfamethoxazole-in-the-case-of-an-enterococcus-faecium-liver-abscess/